Subscribe To
SQZ / SQZ Biotechnologies to Present at Jefferies Healthcare Conference
SQZ News
By Zacks Investment Research
May 10, 2023
SQZ Biotechnologies Company (SQZ) Reports Q1 Loss, Misses Revenue Estimates
SQZ Biotechnologies Company (SQZ) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compa more_horizontal
By Business Wire
June 1, 2022
SQZ Biotechnologies to Present at Jefferies Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic more_horizontal
By Business Wire
April 6, 2022
SQZ Biotechnologies to Present at Upcoming Investor Conferences
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic more_horizontal
By Business Wire
March 8, 2022
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meet
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple the more_horizontal
By Business Wire
March 8, 2022
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meet
WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple the more_horizontal
By Benzinga
December 2, 2021
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Hu more_horizontal
By Benzinga
December 2, 2021
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Hu more_horizontal
By Benzinga
December 2, 2021
SQZ Biotechnologies' Cell Therapy Shows Favorable Safety Profile In HPV+ Solid Tumors
SQZ Biotechnologies Company (NYSE: SQZ) announced interim results from the highest-dose monotherapy cohort of Phase 1/2 trial of SQZ-PBMC-HPV in Hu more_horizontal
